Corcept Therapeutics CORT Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's total cost of revenue?
- Corcept Therapeutics (CORT) reported total cost of revenue of $2.88M in Q1 2026.
- How has Corcept Therapeutics's total cost of revenue changed year-over-year?
- Corcept Therapeutics's total cost of revenue increased by 20.0% year-over-year, from $2.4M to $2.88M.
- What is the long-term trend for Corcept Therapeutics's total cost of revenue?
- Over 4 years (2021 to 2025), Corcept Therapeutics's total cost of revenue has grown at a 25.2% compound annual growth rate (CAGR), from $5.28M to $12.98M.
- What does total cost of revenue mean?
- The direct costs incurred to produce the goods or services that a company sold.
- How do you interpret total cost of revenue?
- A lower ratio relative to revenue indicates higher production efficiency and better gross margins.
- How does total cost of revenue compare across companies?
- Highly dependent on industry; pharmaceutical companies generally maintain low cost of revenue due to high intellectual property value.